| Literature DB >> 32572609 |
Emire Seyahi1, Burc Cagri Poyraz2, Necdet Sut3, Selma Akdogan4, Vedat Hamuryudan5.
Abstract
We hypothesized that patients with rheumatic diseases (RD) would have increased psychological distress during the COVID-19 outbreak; therefore, assessed their psychological symptoms and changes in their routine. A web-based questionnaire survey was conducted in a cross-sectional design in three groups of participants: (1.) patients with RD, (2.) hospital workers, and (3.) high-school teachers/academic staff. Psychiatric status was evaluated using Hospital Anxiety and Depression Scale and Impact of Event Scale-Revised scale. Overall response rate was 34.7%. We studied 771 patients with RD, 535 hospital workers, and 917 teachers/academic staff. Most of the patients with RD were unwilling to go to the hospital (86%), while 22% discontinued their medications. Biological DMARDS were the most frequent drugs whose doses were altered. Only 4% were willing to take hydroxychloroquine for protection. Moreover, the frequency of anxiety (20%), depression (43%), and post-traumatic stress (28%) among patients with RD were found to be comparable to that found among the teachers/academic staff (23%, 43% and 29%, respectively), whereas significantly less than that observed among the hospital workers (40%, 62%, and 46%, respectively) (p < 0.001). Female gender, use of social media, having a comorbid disease, or a psychiatric disorder were found to be independently associated with psychiatric symptoms in total study population. The majority of the patients were unwilling to attend outpatient visits and one-fifth skipped or stopped their immunosuppressive agents. Psychiatric symptoms in patient's and teacher's populations were of considerable clinical concern, despite being significantly lower than that observed among the hospital workers.Entities:
Keywords: Anxiety; COVID-19; Depression; Health workers; Mental health; Outbreak; Post-traumatic stress; Rheumatic diseases; Rheumatology; Sleep disorders
Mesh:
Year: 2020 PMID: 32572609 PMCID: PMC7306572 DOI: 10.1007/s00296-020-04626-0
Source DB: PubMed Journal: Rheumatol Int ISSN: 0172-8172 Impact factor: 3.580
Socio-demographic variables and resources of information about COVID
| Group 1 patients with RD ( | Group 2 hospital workers ( | Group 3 teachers/academic staff ( | ||
|---|---|---|---|---|
| Age, median (min–max), years | 42 (16–81) | 31 (19–58) | 35 (21–79) | < 0.001*†§ |
| Male/female, | 245/526 (0.46) | 181/354 (0.51) | 258/659 (0.39) | 0.058 |
| Educational status, | ||||
| Primary/middle school | 281 (36.4) | 18 (3.4) | 1 (0.1) | < 0.001*†§ |
| High school or higher | 490 (75.6) | 517 (96.6) | 916 (99.9) | |
| Marital status, | ||||
| Married | 701(69) | 284 (53.3) | 602 (66.2) | < 0.001*§ |
| Single | 171 (31) | 249 (46.7) | 308 (33.7) | |
| Have child, | 524 (68.8) | 228 (45.4) | 497 (57.6) | < 0.001*†§ |
| Household size, | ||||
| ≤ 3 | 408 (52.9) | 259 (57.9) | 545 (63.3) | < 0.001† |
| ≥ 4 | 363 (47.1) | 188 (42.1) | 316 (36.7) | |
| Source of information related to COVID-19, | ||||
| TV | 698 (90.5) | 367 (68.6) | 817 (89.1) | < 0.001*§ |
| Social media | 479 (62.1) | 397 (74.2) | 824 (89.9) | < 0.001*†§ |
| Institution | 79 (10.2) | 443 (82.8) | 224 (24.4) | < 0.001*†§ |
| Friends | 167 (21.7) | 303 (56.6) | 428 (46.7) | < 0.001*†§ |
| Social media resources | ||||
| 425 (55.1) | 348 (65.0) | 628 (68.5) | < 0.001*† | |
| 206 (26.7) | 211 (39.4) | 535 (58.3) | < 0.001*†§ | |
| 315 (40.9) | 192 (35.9) | 365 (39.8) | 0.175 | |
| WhatsApp groups | 277 (35.9) | 371 (69.3) | 529 (57.7) | < 0.001*†§ |
| Internet websites | 344 (44.6) | 349 (65.2) | 610 (66.5) | < 0.001* |
| Hours spent daily watching TV/using social media | ||||
| ≤ 1 h | 335 (43.5) | 142 (26.5) | 238 (26.0) | < 0.0001*† |
| ≥ 2hours | 436 (56.5) | 393 (73.5) | 679 (74.0) | |
P* Group 1 vs Group 2, †Group 1 vs Group 3, §Group 2 vs Group 3, Min minimum, Max maximum
COVID–19 diagnosis and risk factors for COVID-19
| Group 1 patients with RD ( | Group 2 hospital workers ( | Group 3 teachers/academic staff ( | ||
|---|---|---|---|---|
| Diagnosed with COVID-19 ( | 4 (0.5) | 14 (2.6) | 3 (0.3) | < 0.001*§ |
| Family relative or close friends diagnosed with COVID-19, | 92 (11.9) | 174 (32.8) | 88 (9.7) | < 0.001*†§ |
| Presence of a relative in the household ≥ 65 years of age, | 367 (48.0) | 274 (51.6) | 525 (57.6) | < 0.001† |
| Smoking status, | ||||
| Active | 290 (37.8) | 201 (37.8) | 390 (42.8) | < 0.001*† |
| Quit | 125 (16.3) | 40 (7.5) | 74 (8.1) | |
| Never | 353 (46.0) | 291 (54.7) | 447 (49.1) | |
| Diagnosed previously with a comorbid disease, | 257 (33.3) | 75 (14.0) | 122 (13.3) | < 0.001*† |
| History of psychiatric disorders or psychiatric drug use for at least three months, | 247 (32.0) | 129 (24.1) | 140 (15.3) | < 0.001*†§ |
P * Group 1 vs Group 2, †Group 1 vs Group 3, §Group 2 vs Group 3
Socio-demographic characteristics and immediate behavior change after the outbreak in different types of rheumatic diseases
| Total | RA | CTD | SpA | BS | FMF | Vasculitis | ||
|---|---|---|---|---|---|---|---|---|
| Age, median (min–max), years | 42 (16–81) | 52 (21 – 81) | 42 (18 – 79) | 40.5 (23 – 71) | 40 (16 – 63) | 28 (18 – 66) | 46 (19 – 76) | < 0.001 |
| Male/ female, | 245/526 | 21/110 | 18/153 | 58/44 | 108/63 | 21/58 | 19/98 | < 0.001 |
| Strict compliance with ‘stay home’ warnings’, | 678 (88.2) | 122 (93.8) | 152 (89.4) | 84 (82.4) | 139 (81.3) | 72 (91.1) | 109 (93.2) | 0.002 |
| Need to go out for work, | 213 (27.8) | 21 (16.0) | 30 (17.5) | 41 (40.6) | 76 (44.7) | 24 (30.8) | 21 (18.1) | < 0.001 |
| Received enough medical support or information, | 591 (72.7) | 103 (78.6) | 131 (76.6) | 78 (76.5) | 129 (75.4) | 63 (79.7) | 87 (74.4) | 0.675 |
| Attended the outpatient clinic, | ||||||||
| Regularly, as it was before | 55 (14.4) | 6 (10.7) | 5 (6.2) | 10 (20.8) | 14 (16.1) | 4 (12.1) | 16 (20.8) | 0.119 |
| Did not want to | 163 (42.7) | 26 (46.4) | 35 (43.2) | 16 (33.3) | 32 (36.8) | 18 (54.5) | 36 (46.8) | |
| Wanted to but could not contact anyone | 59 (15.4) | 9 (16.1) | 11 (13.6) | 10 (20.8) | 13 (14.9) | 7 (21.2) | 9 (11.7) | |
| Was advised not to come | 105 (27.5) | 15 (26.8) | 30 (37.0) | 12 (25.0) | 28 (32.2) | 4 (12.1) | 16 (20.8) | |
| Continued medications** | ||||||||
| Yes, as it was before | 582 (77.6) | 104 (81.3) | 142 (85.5) | 44 (46.3) | 132 (79.5) | 67 (84.8) | 93 (80.2) | < 0.001 |
| Yes but decreased or skipped the dose | 123 (16.4) | 19 (14.8) | 21 (12.7) | 28 (29.5) | 22 (13.3) | 12 (15.2) | 21 (18.1) | |
| No, stopped taking them | 45 (6.0) | 5 (3.9) | 3 (1.8) | 23 (24.2) | 12 (7.2) | 0 | 2 (1.7) | |
RA rheumatoid arthritis, CTD connective tissue diseases, SpA spondylarthropathies, BS Behçet’s syndrome, FMF familial Mediterranean fever, Min minimum, Max maximum, *n = 382, **n = 750
The prescribed drugs and those whose doses were either skipped or stopped
| Drugs | Dose decreased, skipped or stopped, | Total prescribed, | % |
|---|---|---|---|
| Biological DMARDs | |||
| Anti-tumor necrosis factor agents | 66 | 191 | 34.6 |
| Tocilizumab | 7 | 24 | 29.2 |
| Anti-IL-1 agents | 6 | 15 | 40.0 |
| Rituximab | 5 | 75 | 6.7 |
| Interferon | 3 | 9 | 33.3 |
| Non-biological DMARDs | |||
| Azathioprine | 18 | 187 | 9.6 |
| Methotrexate | 12 | 149 | 8.0 |
| Leflunomide | 2 | 26 | 7.7 |
| Mycophenolate mofetil/sodium | 6 | 29 | 20.7 |
| Sulfasalazine | 6 | 69 | 8.7 |
| Others | |||
| Corticosteroids | 32 | 340 | 9.4 |
| Hydroxychloroquine | 21 | 198 | 10.6 |
| Colchicine | 19 | 194 | 9.8 |
| Cyclophosphamide | 3 | 12 | 25.0 |
DMARDs disease-modifying anti-rheumatic drugs
Psychiatric symptoms
| Group 1 Patients with RD | Group 2 Hospital workers | Group 3 teachers/academic staff | ||
|---|---|---|---|---|
| HAD anxiety level, median (min–max) | 7 (0–20) | 9 (0–21) | 7 (0–21) | < 0.001*§ |
| ≥ 11 cut-off, | 148 (19.6) | 200 (39.8) | 202 (23.1) | < 0.001*§ |
| HAD depression level, median (min–max) | 7 (0–21) | 9 (0–21) | 7 (0–19) | < 0.001*§ |
| ≥ 8 cut-off, | 324 (42.8) | 309 (61.6) | 373 (42.7) | < 0.001*§ |
| IES-R (total), median (min–max) | 22 (0–77) | 31 (0–79) | 24 (0–81) | < 0.001*§ |
| Intrusion | 6 (0–29) | 10 (0–32) | 7 (0–29) | < 0.001*§ |
| Avoidance | 11 (0–28) | 12 (0–28) | 12 (0–31) | 0.012† |
| Hyperarousal | 5 (0–24) | 8 (0–24) | 5 (0–24) | < 0.001*§ |
| PTS cut-off (≥ 33) | 210 (28.4) | 219 (46.4) | 232 (29.1) | < 0.001*§ |
| Sleep disturbances, | ||||
| Trouble staying asleep | 175 (23.7) | 139 (29.4) | 128 (16.0) | < 0.001*†§ |
| Trouble falling asleep | 176 (23.8) | 139 (29.4) | 145 (18.2) | < 0.001*†§ |
| Is the outbreak dangerous? | 0.001*§ | |||
| Very dangerous | 681 (88.3) | 432 (81.2) | 792 (86.6) | |
| Partly or no dangerous at all | 90 (11.7) | 103 (18.8) | 125 (13.4) | |
RD rheumatic disease, HADS Hospital anxiety and depression scale, IES-R impact of event scale-revised version, PTS post-traumatic stress
P* Group 1 vs Group 2, †Group 1 vs Group 3, §Group 2 vs Group 3
Effect of socio-demographic variables, resources of information about COVID-19, COVID–19 diagnosis, and risk factors for COVID-19 on anxiety, depression, and IES-R
| HADS-anxiety ≥ 11 | HADS-depression ≥ 8 | IES-R ≥ 33 | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | P | |||
| Groups | ||||||
| Group 1 (patients with RD) | 0.39 (0.28–0.54) | < 0.001 | 0.52 (0.39–0.70) | < 0.001 | 0.45 (0.33–0.62) | < 0.001 |
| Group 3 (teachers/academic staff) | 0.50 (0.37–0.67) | < 0.001 | 0.52 (0.40–0.68) | < 0.001 | 0.51 (0.38–0.69) | < 0.001 |
| Age, 1 year increase | 0.95 (0.93–0.96) | < 0.001 | 0.97 (0.96–0.98) | < 0.001 | 0.97 (0.95–0.98) | < 0.001 |
| Gender, being female | 3.07 (2.29–4.12) | < 0.001 | 1.57 (1.27–1.95) | < 0.001 | 2.54 (1.97–3.29) | < 0.001 |
| Length of education, ≤ 8 years | 1.60 (1.07–2.40) | 0.023 | 1.11 (0.80–1.53) | 0.548 | 1.78 (1.24–2.54) | 0.002 |
| Marital status, being single | 0.81 (0.58–1.11) | 0.190 | 0.84 (0.64–1.10) | 0.216 | 0.99 (0.73–1.33) | 0.944 |
| Have child, yes | 1.59 (1.11–2.26) | 0.011 | 1.17 (0.88–1.58) | 0.283 | 1.59 (1.14–2.20) | 0.006 |
| Household size, ≥ 4 | 1.32 (1.04–1.68) | 0.022 | 1.12 (0.92–1.37) | 0.262 | 0.96 (0.77–1.20) | 0.710 |
| Time spent watching TV or using social media, > 1 h | 1.44 (1.10–1.88) | 0.008 | 1.33 (1.07–1.65) | 0.010 | 1.43 (1.12–1.83) | 0.004 |
| Presence of COVID-19 in the participant, or in family or close friends, Yes | 1.52 (1.13–2.04) | 0.005 | 1.48 (1.13–1.95) | 0.005 | 1.31 (0.99–1.75) | 0.062 |
| Presence of a relative in the household ≥ 65 years of age, Yes | 1.17 (0.93–1.48) | 0.190 | 1.24 (1.02–1.5) | 0.033 | 1.19 (0.96–1.48) | 0.108 |
| Smoking status, Active or quit | 1.25 (0.99–1.58) | 0.057 | 1.39 (1.14–1.69) | 0.001 | 1.38 (1.11–1.72) | 0.004 |
| Comorbid diseases, Yes | 1.45 (1.11–1.89) | 0.006 | 1.67 (1.33–2.10) | < 0.001 | 1.55 (1.21–1.99) | < 0.001 |
| History of psychiatric disorders or psychiatric drug use for at least 3 months, | 1.95 (1.50–2.54) | < 0.001 | 1.38 (1.09–.74) | 0.008 | 1.49 (1.16–1.92) | 0.002 |
Reference categories are as follows: Group 2 (hospital workers) for Group variable, 1 year decrease for age, being male for gender, > 8 years for length of education, being married for marital status, no for having child, ≤ 3 for household size, ≤ 1 h for time spent watching TV or using social media, no for presence of COVID-19 in the participant or family, no for the presence of a relative in the household of ≥ 65 years of age, never for smoking status, none for comorbid diseases, and none for history of psychiatric disorders or psychiatric drug use for at least 3 months